Skip to main content
Download PDF

Comparing the efficacy of thyroglobulin and thyroglobulin/ thyroid-stimulating hormone ratio models in predicting a successful response to radioactive iodine therapy

BMC Endocrine Disorders volume 23, Article number: 19 (2023) Cite this article

Abstract

Background

The thyroglobulin (Tg)/ thyroid-stimulating hormone (TSH) ratio has manifested to be a reliable marker for predicting prognosis in patients with differentiated thyroid carcinoma (DTC). The objective of this study was to compare the efficacy of Tg and Tg/TSH ratio models in predicting a successful response to radioactive iodine therapy.

Methods

One thousand six hundred forty-two DTC patients receiving 131I radiotherapy were finally enrolled in this retrospective study. The patients were divided into a training set (n = 973) and a validation set (n = 669) by the patient consultation time (July 2019). A receiver-operating characteristic curve was constructed for Tg and the Tg/TSH ratio to establish their cutoffs. Then, the variables were screened by univariate logistic regression and incorporated into logistic prediction models by stepwise regression, where Tg/TSH was excluded from model 1 and Tg was excluded from model 2.

Results

In 1642 enrolled DTC patients, the first 131I radiotherapy had an excellent response in 855 patients. The cut-offs for Tg level and Tg/TSH ratio were 3.40 ng/ mL [area under the curve (AUC): 0.789] and 36.03 ng/mIU (AUC: 0.788), respectively. In addition, the AUC of the model including Tg was higher than that of the model including Tg/TSH in both the training set (0.837 vs 0.833) and the testing set (0.854 vs 0.836).

Conclusions

Both Tg and Tg/TSH ratios could be considered predictors of the effects of the first 131I ablative therapy. However, the prediction model including Tg performed better than the model including Tg/TSH.

Peer Review reports

Introduction

Thyroid cancer ranked 9th for incidence in 2020 and is the most common endocrine malignancy worldwide [1, 2]. Of all the thyroid carcinoma, differentiated thyroid cancer (DTC) accounts for nearly 90% [3]. The standard treatment for DTC is total or near-total thyroidectomy followed by radioactive iodine (RAI) therapy and thyroid-stimulating hormone (TSH) suppression with levothyroxine (L-T4). With this treatment approach, the majority of patients with DTC could get improved disease-free survival and long-term prognosis [4]. However, in some patients, the persistent disease develops after initial treatment, or cancer recurrence is detected during follow-up.

The RAI could destroy the remaining residual tissue or metastatic tissue susceptible to radioiodine uptake, and is crucial to the treatment of thyroid cancer [5]. Its results affect the prognosis of patients with DTC and guide the decision-making process leading to RAI treatment. Thyroglobulin (Tg) has been demonstrated to be critical in predicting therapeutic response to RAI [6,7,8]. Since the production of Tg could be stimulated by the TSH, Tg values may be affected by the TSH values of pre-ablative patients. For this reason, the relationship between the Tg/TSH ratio and the outcome of the first 131I radiotherapy has been extensively studied [9,10,11]. However, few studies have compared the predictive model capability to the RAI ablation therapy of Tg and Tg/TSH.

This study aimed to assess the factors affecting the outcome of the first 131I radiotherapy in patients with DTC and compare the efficacy of Tg and Tg/TSH ratio models in predicting a successful response to radioactive iodine therapy.

Material and methods

Study patients

This retrospective study reviewed the clinical records of 2331 DTC patients treated consecutively at our institution between September 2015 and September 2020. Patients’ data were extracted from the clinical electronic medical record system of the Second Hospital of Shandong University. Inclusion criteria were as follows:(1) adult patients with anatomopathological DTC diagnosis, (2) patients who received total or near-total thyroidectomy, and (3) patients who received 131I treatment followed. Exclusion criteria were as follows:(1) patients who presented thyroglobulin antibody (TgAb) ≥ 115 IU/ml, (2) patients who lost to follow-up and had inadequate information (Fig. 1). After the inclusion and exclusion criteria screening, 1642 patients were finally enrolled in this study.

Fig. 1
figure 1

The flow chart of the study

Full size image

Patient data extracted from the clinical electronic medical record system was identified such that all private information was not included. The informed consent was waived by the Institutional Review Board of the Second Hospital of Shandong University [KYLL-2018(LW)013]. All procedures complied with the Declaration of Helsinki for research involving human subjects.

Treatment and examination

All patients underwent L-T4 withdrawal or no L-T4 therapy after total or near-total thyroidectomy for 3–4 weeks, accompanied by a low-iodine diet (< 50 ugs per day) for 1–2 weeks. When prepared well, a treatment dose from 1.11 GBq (30 mCi) to 5.55 GBq (150 mCi) of 131I was given on an empty stomach according to their tumor stage and recurrence risk stratification. The following tests were completed within three days before 131I treatment, including TSH, free thyroxine, free triiodothyronine, Tg, and TgAb.

Evaluation of the therapeutic effect of 131I radiotherapy

Approximately six months after the 131I treatment, the curative efficacy was evaluated. The risk assessment after the initial 131I treatment was analyzed according to the 2015 American Thyroid Association (ATA) guideline, and the clinical therapeutic results were divided into four categories: Excellent Response (ER), Indeterminate Response (IDR), Biochemical Incomplete Response (BIR), and Structural Incomplete Response (SIR). The analysis classified the four response-to-therapy categories into ER and non-excellent response (NER), the latter including IDR, BIR, and SIR.

Statistical analysis

Continuous variables were reported as mean and standard deviation or median values and quartiles, while categorical variables were reported as numbers and percentages. Between groups, differences were assessed with the student t-test (and Mann–Whitney U test) or the chi‑square test (categorical variables). The patients were divided into a training set (n = 973) and a validation set (n = 669) by the patient consultation time (July 2019). A receiver-operating characteristic (ROC) curve was constructed for Tg and the Tg/TSH ratio to establish their cutoffs. Then, univariate logistic regression was used to screen the factors associated with RAI therapy efficacy. The screened variables were incorporated into logistic prediction models by stepwise procedure, where Tg/TSH was excluded from model 1 and Tg was excluded from model 2. The performance of the models was evaluated by the AUC, accuracy, and specificity. The accuracy and clinical benefit of the model were assessed by the calibration curves and decision curves, separately. All tests were two-sided, and a P-value < 0.05 was considered statistically significant. The statistical analysis was performed on the software package R (version 4.1.1).

Results

Characteristics of patients

Of the 1642 DTC patients receiving 131I thyroid remnant ablation, the mean age at diagnosis was 43.69(± 11.50) years, and the majority (n = 1162; 70.8%) of DTC were female. Characteristics of study subjects are presented in Table 1.

Table 1 Comparison of baseline information for the training and testing sets
Full size table

Comparison between excellent response and non-excellent response groups

In 1642 enrolled DTC patients, the first 131I thyroid remnant ablation had an excellent response in 787 patients and had an incomplete answer in the remaining 855 patients, with a rate of excellent response of 52.1%. The differences in gender, metastasis number, benign lesion, ATA risk stratification, Tg and Tg/TSH ratio between patients with successful and unsuccessful ablation were statistically significant. (P < 0.05) (Table 2).

Table 2 Clinical pathologic characteristics of the cohort
Full size table

Analysis of the factors affecting the efficacy of 131I radiotherapy

Univariate analysis showed that the outcome of 131I radiotherapy was influenced by age, gender, metastasis number, with or without benign lesion, Tumor-node-metastasis (TNM) stage, ATA risk stratification, pre-treatment Tg level and Tg/TSH level (Fig. 2).

Fig. 2
figure 2

Univariate analysis of the excellent response (ER) of radioactive iodine. TNM stage, Tumor-node-metastasis stage of patients; TSH, Thyroid stimulating hormone; Tg, Thyroglobulin; OR, Odds ratio; CI, Confidence interval

Full size image

According to the ROC curve, the cut-offs for the Tg level was 3.40 ng/ mL [area under the curve (AUC): 0.789] with 63.4% sensitivity and 84.0% specificity, while for Tg/TSH ratio was 36.03 ng/mIU (AUC: 0.788) with 67.2% sensitivity and 81.5% specificity (Fig. 3).

Fig. 3
figure 3

Receiver-operating characteristic (ROC) curves of the thyroglobulin [A: cutoff = 3.40 ng/mL (area under the curve: 0.789) with 63.4% sensitivity and 84.0% specificity] and regarding thyroglobulin/thyroid-stimulating hormone ratio [B: cutoff = 36.03 ng/mIU (area under the curve: 0.788) with 67.2% sensitivity and 81.5% specificity] as predictors of successful radioiodine therapy

Full size image

Age, sex, ATA risk stratification and Tg level were all independent influencers of RAI success in model 1, and age, sex, ATA risk stratification and Tg/TSH level were all independent influencers of RAI success in model 2 (P < 0.05) (Table 3). The AUC of model 1 was higher than that of model 2 in both the training set (0.837 vs 0.833) and the testing set (0.854 vs 0.836) (Table 4). Besides, both the ROC curve and decision curve of model 1 in the validation set were significantly higher than that of model 2 (Fig. 4).

Table 3 Multiple logistic regression to the successful radioiodine therapy
Full size table
Table 4 The ability of models to predict successful radioiodine therapy in the training set and testing set
Full size table
Fig. 4
figure 4

The ROC curves (A, B), Decision Curves (C, D), and Calibration Curves (E, F) of the 2 models. Model 1, multiple logistic analysis consisting of age, sex, ATA risk stratification and Tg to the successful radioactive iodine; Model 2, multiple logistic analysis consisting of age, sex, ATA risk stratification and Tg/TSH to the successful radioactive iodine; ROC, Receiver-operating characteristic; TSH, Thyroid stimulating hormone; Tg, Thyroglobulin

Full size image

Discussion

Unsuccessful ablation may adversely affect the prognosis of patients with DTC; therefore, predicting the outcome of RAI treatment is important to the treatment and follow-up protocols of patients with DTC. Tg is a glycoprotein that is explicitly produced by thyroid cells and has been demonstrated as a prognosis predictor implying 131I therapy response before RAI [12,13,14]. Since TSH is the trigger factor that directly affects the expression of Tg [15], many have studied the Tg/TSH ratio in addition to Tg to investigate the predictive value for RAI therapy in patients with DTC [16, 17]. Some studies have reported that both Tg and Tg/TSH ratios could be considered predictors of the effects of RAI therapy [9, 18].

In this study, the cutoffs were 3.40 ng/ mL for Tg and 36.03 ng/mIU for the Tg/TSH ratio in predicting successful RAI according to the ROC curve. Though the cutoffs differed from the results of previous studies due to various measurement kits with different sensitivities and display units, this study reached similar findings to some studies that the Tg/TSH ratio and Tg were equally reliable in predicting successful RAI in DTC patients [9, 18]. However, Other studies had different views on the comparison of Tg and Tg/TSH. Some researchers have found that Tg/TSH ratio had a stronger association with ablation outcome than Tg [10]; While others considered that the predictive value of the Tg/TSH ratio was inferior to the prognostic value of Tg alone [19]. The comparison of the Tg and Tg/TSH ratio in predicting the outcome of RAI treatment remained controversial.

To further compare the predictive performance of Tg and Tg/TSH to the response of the RAI therapy, we constructed 2 predictive models and compared them in the training and validation sets respectively. The study showed that in the testing set, the AUC of the predictive model including Tg to predict successful ablation was 0.854 with 75.3% sensitivity and 82.3% specificity, while the AUC of the predictive model including Tg/TSH was 0.836 with 74.7% sensitivity and 79.2% specificity. In addition, the ROC curves and decision curves also showed that the predictive model including Tg performed better in predicting the results of RAI therapy in patients with DTC. Thus, in the present study, the model including Tg had greater predictive accuracy and higher clinical benefit than the model including Tg/TSH. This showed that Tg was a better predictor of the DTC effect than Tg/TSH in the clinical setting.

Compared with other studies, our study included a relatively large number of participants, the outcome of each participant was observed by ourselves, and there was almost no recall bias; In addition, we also conducted a sensitivity analysis by dividing the training set and the validation set to verify the performance of the model, and the research results are convincing. There are several limitations to this study. First of all, the data about TSH tests at several time points could not be analyzed in this study, which was not available in routine practice. Besides, this study had a relatively short follow-up time, and the long-term clinical implication of the Tg and Tg/TSH needs to be assessed by additional prospective studies.

Conclusion

In conclusion, the present study found that both the Tg and the Tg/TSH ratio could affect the effects of RAI therapy, and the prediction model including Tg performed better than the model including Tg/TSH. Consequently, Tg was more recommended as the factor to predict the efficacy of RAI therapy given its better predictive efficacy in this study.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

Abbreviations

DTC:

Differentiated thyroid cancer

RAI:

Radioactive iodine

TSH:

Thyroid-stimulating hormone

L-T4:

Levothyroxine

ATA:

American Thyroid Association

Tg:

Thyroglobulin

TgAb:

Thyroglobulin antibody

ER:

Excellent Response

IDR:

Indeterminate Response

BIR:

Biochemical Incomplete Response

SIR:

Structural Incomplete Response

NER:

Non-excellent response

TNM:

Tumor-node-metastasis

References

  1. Siegel RA-O, Miller KA-O, Fuchs HE, Jemal A. 2021 Cancer Statistics. CA Cancer J Clin. 2021;71(1):7–33.

    Article  Google Scholar 

  2. Sung HA-O, Ferlay J, Siegel RA-O, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  Google Scholar 

  3. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388(10061):2783–95.

    Article  CAS  Google Scholar 

  4. McLeod DS. Sawka Am Fau - Cooper DS, Cooper DS: Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet. 2013;381(9871):1046–57.

    Article  Google Scholar 

  5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.

    Article  Google Scholar 

  6. Fatemi S, LoPresti JS. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(9):4507–8.

    Article  CAS  Google Scholar 

  7. Amui IO, Tagliarini JV, Castilho EC, Marques MA, Kiy Y, Corrente JE, Mazeto G. The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomas. Braz J Otorhinolaryngol. 2019;85(1):37–42.

    Article  Google Scholar 

  8. Webb RC, Howard RS, Stojadinovic A, Gaitonde DY, Wallace MK, Ahmed J, Burch HB. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab. 2012;97(8):2754–63.

    Article  CAS  Google Scholar 

  9. Lin Y, Li T, Liang J, Li X, Qiu L, Wang S, Chen Y, Kang Z, Li F. Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio in differentiated thyroid cancer. Clin Nucl Med. 2011;36(12):1102–5.

    Article  Google Scholar 

  10. Zubair Hussain S, Zaman MU, Malik S, Ram N, Asghar A, Rabbani U, Aftab N, Islam N. Preablation stimulated thyroglobulin/TSH ratio as a predictor of successful I (131) remnant ablation in patients with differentiated thyroid cancer following total thyroidectomy. J Thyroid Res. 2014;2014:610273.

    Article  Google Scholar 

  11. De Marchi AF, de Macedo ABT, Soares CSP, Bolfi F, Iessi MRG, de Oliveira CC, Koga KH, Moriguchi SM, Tagliarini JV, da Silva Mazeto GMF. Thyroglobulin/thyrotropin ratio for predicting long-term response in differentiated thyroid carcinoma: a retrospective study. Arch Endocrinol Metab. 2021;65(4):428–35.

    Google Scholar 

  12. Prpić M, Franceschi M, Romić M, Jukić T, Kusić Z. Thyroglobulin as a tumor marker in differentiated thyroid cancer - clinical considerations. Acta Clin Croat. 2018;57(3):518–27.

    Google Scholar 

  13. Jayasekara J, Jonker P, Lin JF, Engelsman AF, Wong MS, Kruijff S, Aniss A, Learoyd D, Bligh RC, Glover A, et al. Early postoperative stimulated serum thyroglobulin quantifies risk of recurrence in papillary thyroid cancer. Surgery. 2020;167(1):40–5.

    Article  Google Scholar 

  14. Nóbrega G, Cavalcanti M, Leite V, Vilar L, Brandão SCS. Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine. Endocrine. 2022;76(3):642–7.

    Article  Google Scholar 

  15. Coscia F, Taler-Verčič A, Chang VT, Sinn L, O’Reilly FJ, Izoré T, Renko M, Berger I, Rappsilber J, Turk D, et al. The structure of human thyroglobulin. Nature. 2020;578(7796):627–30.

    Article  CAS  Google Scholar 

  16. Zheng W, Rui Z, Wang X, Li N, Tan J, Liu W. The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of (131)I Treatment in DTC Patients. Front Endocrinol (Lausanne). 2021;12:601960.

    Article  Google Scholar 

  17. Wang C, Diao H, Ren P, Wang X, Wang Y, Zhao W. Efficacy and affecting factors of (131)I thyroid remnant ablation after surgical treatment of differentiated thyroid carcinoma. Front Oncol. 2018;8:640.

    Article  Google Scholar 

  18. Trevizam PG, Tagliarini JV, Castilho EC, de Alencar MM, Kiy Y, Mazeto G. Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic (131)I in the differentiated thyroid cancers. Endocr Res. 2017;42(1):42–8.

    Article  CAS  Google Scholar 

  19. Prpic M, Kruljac I, Kust D, Kirigin LS, Jukic T, Dabelic N, Bolanca A, Kusic Z. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma. Endocrine. 2016;52(3):602–8.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This project was supported by the basic research projects for free exploration of local science and technology development funds under the guidance of the central government (grant no.2021Svup070), the Research Development Fund of The Second Hospital of Shandong University (grant no.11681808), and Jinan clinical medical science and technology innovation plan (grant no. 202019194).

Author information

Author notes

  1. Yanli Ju and Lihua Wang have contributed equally to this work and share the first authorship.

Authors and Affiliations

  1. Department of Epidemiology and Health Statistics, School of Public Health, Cheeloo College of Medicine, Shandong University, No. 44 Wenhua West Road, Jinan, Shandong, 250012, China

    Yanli Ju, Lihua Wang, Fang Cheng, Fengyan Huang, Xueyu Chen, Qingqing Song & Hongying Jia

  2. Center of Evidence-Based Medicine, the Second Hospital, Cheeloo College of Medicine, Shandong University, No. 247 Beiyuan Street, Jinan, Shandong, 250033, China

    Juan Xiao & Hongying Jia

  3. Department of Nuclear Medicine, the Second Hospital, Cheeloo College of Medicine, Shandong University, No. 247 Beiyuan Street, Jinan, Shandong, 250033, China

    Xiaolu Zhu

Authors
  1. Yanli Ju
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lihua Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fang Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fengyan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xueyu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qingqing Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Juan Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiaolu Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hongying Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HY J and XL Z designed the study. YL J and LH W contributed to data analysis, data interpretation, and manuscript writing. F C and FY H contributed to data collection and data analysis. XY C revised the manuscript. QQ S and J X participated in preparing the figures and tables. All the authors read and approved the final manuscript.

Corresponding authors

Correspondence to Xiaolu Zhu or Hongying Jia.

Ethics declarations

Ethics approval and consent to participate

Patient data extracted from the clinical electronic medical record system was identified such that all private information was not included. The Institutional Review Board (IRB) of the Second Hospital of Shandong University approved the use of records and allowed us not to obtain written consent from each patient [KYLL-2018(LW)013]. All procedures complied with the Declaration of Helsinki for research involving human subjects.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ju, Y., Wang, L., Cheng, F. et al. Comparing the efficacy of thyroglobulin and thyroglobulin/ thyroid-stimulating hormone ratio models in predicting a successful response to radioactive iodine therapy. BMC Endocr Disord 23, 19 (2023). https://doi.org/10.1186/s12902-022-01261-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12902-022-01261-7

Keywords

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us